Atisama Therapeutics Appoints Young Kwon PhD as Non-Executive Director

• Dr Kwon joins the Board to help shape Atisama’s strategy and capital pathway as the Company advances its splice-switching oligonucleotide (SSO) platform.

• Atisama’s lead asset, RB042, an inhaled SSO therapy for COPD, in Phase 1, with a growing pipeline of SSO programmes across lung, liver, kidney, ocular and CNS indications.

• Dr Kwon brings more than 25 years as an investor and senior executive in private and public biotech companies, including as CEO of Alchemab Therapeutics and CFBO of Momenta Pharmaceuticals, with experience across capital raising, partnering and M&A.

MELBOURNE, AUSTRALIA, 14 October 2026 – Atisama Therapeutics (“Atisama” or the “Company”), a clinical-stage biotechnology company developing precision splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today announced the appointment of Dr Young Kwon to its Board of Directors as a Non-Executive Director, effective 1 October 2026.

Appointment of Dr Young Kwon to the Board

Dr Kwon joins Atisama as the Company builds out its SSO platform and pipeline, led by RB042, an inhaled SSO therapy for COPD now in early clinical development. He will work with the Board and management on strategy and the capital pathway, from future financing rounds through to potential public markets.

A Boston-based investor and executive, Dr Kwon has more than 25 years’ experience in private and public biotech. He has led capital raises, partnerships and M&A deals. At Momenta Pharmaceuticals, he led the company’s US$6.5 billion sale to Johnson & Johnson. As CEO of Alchemab Therapeutics, he took the company from a platform concept to two lead candidates and an ALS collaboration with Eli Lilly. He currently sits on the Board of ADMA Biologics (Nasdaq: ADMA).

Earlier, at Biogen, he led business development transactions including a collaboration on an inhaled peptide for pulmonary arterial hypertension. He holds a PhD from Harvard University and a BS from the Massachusetts Institute of Technology (MIT).

“I’m delighted to welcome Young to the Atisama Board. He brings the perspective of both an investor and a senior executive in private and public biotech companies, and has led capital raising, partnering and M&A transactions with some of the world’s leading pharmaceutical companies. He joins us to help shape our strategy and capital pathway as we advance RB042 and the broader SSO pipeline,” said Dr Siro Perez, Chief Executive at Atisama Therapeutics.

“Atisama has a differentiated, clinical-stage inhaled drug candidate that takes a novel approach to a genetically validated driver of inflammation, and a platform that could extend well beyond respiratory disease. I am excited to work with Siro, the Board and the team to maximize the value of the lead program and the broader pipeline,” said Dr Young Kwon, Non-Executive Director at Atisama Therapeutics.

About Atisama Therapeutics

Atisama Therapeutics Pty Ltd (ACN 640 194 770, formerly Rage Bio Pty Ltd) is a clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapies for inflammatory disease. Founded on the principle of restoring molecular balance for lasting health, the Company’s SSO platform is producing drug candidates that down-regulate disease-driving isoforms and upregulate their protective counterparts, a dual-action mechanism unique to the SSO modality. Atisama’s lead asset, RB042, is an inhaled SSO currently in Phase 1 clinical development. Atisama has a pipeline of programmes leveraging the novel SSO platform. The Company is headquartered in Melbourne, Australia.

About RB042

RB042 is an inhaled splice-switching oligonucleotide (SSO) targeting the Receptor for Advanced Glycation End-products (RAGE), a genetically validated driver of inflammation in chronic obstructive pulmonary disease (COPD). RB042 redirects pre-mRNA splicing to the protective soluble esRAGE isoform over pro-inflammatory membrane-bound mRAGE, potentially shifting the isoform balance disrupted in disease. RB042 is currently being evaluated in a Phase 1 study (RB042_1001; NCT07285122) in healthy volunteers and healthy smokers across single ascending dose and multiple ascending dose cohorts. COPD affects approximately 400 million people globally and is the third leading cause of death worldwide; approximately 70% of patients are non-eosinophilic and lack a targeted therapeutic option. RB042 is being developed across all COPD endotypes, with additional indications under evaluation.

For more information, visit www.atisama.com or contact media@atisama.com.